Biochemical biomarkers alterations in Coronavirus Disease 2019 (COVID-19)

Marcello Ciaccio, Luisa Agnello, Marcello Ciaccio, Luisa Agnello

Abstract

Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a respiratory disease, which can evolve into multi-organ failure (MOF), leading to death. Several biochemical alterations have been described in COVID-19 patients. To date, many biomarkers reflecting the main pathophysiological characteristics of the disease have been identified and associated with the risk of developing severe disease. Lymphopenia represents the hallmark of the disease, and it can be detected since the early stage of infection. Increased levels of several inflammatory biomarkers, including c-reactive protein, have been found in COVID-19 patients and associated with an increased risk of severe disease, which is characterised by the so-called "cytokine storm". Also, the increase of cardiac and liver dysfunction biomarkers has been associated with poor outcome. In this review, we provide an overview of the main biochemical characteristics of COVID-19 and the associated biomarkers alterations.

Keywords: COVID-19; SARS-CoV-2; biochemical alterations; biomarkers; laboratory.

References

    1. Rocklov, J, Sjodin, H, Wilder-Smith, A. COVID-19 outbreak on the Diamond Princess Cruise ship: estimating the epidemic potential and effectiveness of public health countermeasures. J Travel Med 2020. [Epub ahead of print].
    1. Chan, JF, To, KK, Tse, H, Jin, DY, Yuen, KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013;21:544–55. .
    1. Zhong, N, Zheng, B, Li, Y, Poon, L, Xie, Z, Chan, K, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet 2003;362:1353–8. .
    1. Wang, N, Shi, X, Jiang, L, Zhang, S, Wang, D, Tong, P, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013;23:986–93. .
    1. Li, W, Shi, Z, Yu, M, Ren, W, Smith, C, Epstein, JH, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005;310:676–9. .
    1. Corman, VM, Ithete, NL, Richards, LR, Schoeman, MC, Preiser, W, Drosten, C, et al. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol 2014;88:11297–303. .
    1. Zhou, M, Zhang, X, Qu, J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020;14:126–35. [Epub ahead of print].
    1. Ji, W, Wang, W, Zhao, X, Zai, J, Li, X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol 2020;92:433–40. .
    1. Liu, Y, Yang, Y, Zhang, C, Huang, F, Wang, F, Yuan, J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364–74. .
    1. Xu, H, Zhong, L, Deng, J, Peng, J, Dan, H, Zeng, X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 2020;12:8. .
    1. Lippi, G, Plebani, M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med 2020;58:1131–4.
    1. Siddiqi, HK, Mehra, MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant 2020. [Epub ahead of print].
    1. Yang, W, Cao, Q, Qin, L, Wang, X, Cheng, Z, Pan, A, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020;80:388–93. .
    1. Akhmerov, A, Marban, E. COVID-19 and the heart. Circ Res 2020;126:1443–55. [Epub ahead of print].
    1. Xu, Z, Shi, L, Wang, Y, Zhang, J, Huang, L, Zhang, C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420–2. .
    1. Roe, K. Explanation for COVID-19 infection neurological damage and reactivations. Transbound Emerg Dis 2020; [Epub ahead of print].
    1. Guan, WJ, Ni, ZY, Hu, Y, Liang, WH, Ou, CQ, He, JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020. [Epub ahead of print].
    1. Chen, N, Zhou, M, Dong, X, Qu, J, Gong, F, Han, Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13. .
    1. Huang, C, Wang, Y, Li, X, Ren, L, Zhao, J, Hu, Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. .
    1. Wang, D, Hu, B, Hu, C, Zhu, F, Liu, X, Zhang, J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. J Am Med Assoc 2020;323:1061–69. [Epub ahead of print].
    1. Zhang, G, Zhang, J, Wang, B, Zhu, X, Wang, Q, Qiu, S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir Res 2020;21:74. .
    1. Liao, YC, Liang, WG, Chen, FW, Hsu, JH, Yang, JJ, Chang, MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol 2002;169:4288–97. .
    1. Lai, CC, Liu, YH, Wang, CY, Wang, YH, Hsueh, SC, Yen, MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect 2020. [Epub ahead of print].
    1. Qin, C, Zhou, L, Hu, Z, Zhang, S, Yang, S, Tao, Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020. [Epub ahead of print].
    1. Mo, P, Xing, Y, Xiao, Y, Deng, L, Zhao, Q, Wang, H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020. [Epub ahead of print].
    1. Lippi, G, Plebani, M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med 2020;58:1063–9.
    1. Liu, Y, Du, X, Chen, J, Jin, Y, Peng, L, Wang, HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect 2020. . [Epub ahead of print].
    1. Lagunas-Rangel, FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. J Med Virol 2020. [Epub ahead of print].
    1. Xu, P, Zhou, Q, Xu, J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol 2020. [Epub ahead of print].
    1. Eickmann, M, Gravemann, U, Handke, W, Tolksdorf, F, Reichenberg, S, Müller, TH, et al. Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. Vox Sang 2020;115:146–51. .
    1. Pilaczyńska-Cemel, M, Gołda, R, Dąbrowska, A, Przybylski, G. Analysis of the level of selected parameters of inflammation, circulating immune complexes, and related indicators (neutrophil/lymphocyte, platelet/lymphocyte, CRP/CIC) in patients with obstructive diseases. Cent Eur J Immunol 2019;44:292–8. .
    1. Shinya, K, Gao, Y, Cilloniz, C, Suzuki, Y, Fujie, M, Deng, G et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol 2012;86:6055–66. .
    1. Matsumoto, H, Kasai, T, Sato, A, Ishiwata, S, Yatsu, S, Shitara, J, et al. Association between C-reactive protein levels at hospital admission and long-term mortality in patients with acute decompensated heart failure. Heart Ves 2019;34:1961–8.
    1. Wang, L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect 2020; 50:332–4. [Epub ahead of print].
    1. Tan, C, Huang, Y, Shi, F, Tan, K, Ma, Q, Chen, Y, et al. C-reactive protein correlates with CT findings and predicts severe COVID-19 early. J Med Virol 2020. [Epub ahead of print].
    1. Lippi, G, Plebani, M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta 2020;505:190–1. .
    1. Tosato, F, Giraudo, C, Pelloso, M, Musso, G, Piva, E, Plebani, M. One disease, different features: COVID-19 laboratory and radiological findings in three Italian patients. Clin Chem Lab Med 2020;58:1149–51.
    1. Zhou, F, Yu, T, Du, R, Fan, G, Liu, Y, Liu, Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. .
    1. Zhang, JJ, Dong, X, Cao, YY, Yuan, YD, Yang, YB, Yan, YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2010. [Epub ahead of print].
    1. Yin, S, Huang, M, Li, D, Tang, N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 2020. [Epub ahead of print].
    1. Levi, M, van der Poll, T. Coagulation and sepsis. Thromb Res 2017; 149:38–44. .
    1. Schmitt, FCF, Manolov, V, Morgenstern, Fleming T, Heitmeier, S, Uhle, FJ, et al. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 2019; 9:19. .
    1. Bikdeli, B, Madhavan, MV, Jimenez, D, Chuich, T, Dreyfus, I, Driggin, E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020. [Epub ahead of print].
    1. Terpos, E, Ntanasis-Stathopoulos, I, Elalamy, I, Kastritis, E, Sergentanis, TN, Politou, M, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020. [Epub ahead of print].
    1. Tang, N, Bai, H, Chen, X, Gong, J, Li, D, Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020. [Epub ahead of print].
    1. Wu, C, Chen, X, Cai, Y, Xia, J, Zhou, X, Xu, S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. [Epub ahead of print].
    1. Samama, MM, Cohen, AT, Darmon, JY, Desjardins, L, Eldor, A, Janbon, C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793–800. .
    1. Leizorovicz, A, Cohen, AT, Turpie, AG, Olsson, CG, Vaitkus, PT, Goldhaber, SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874–9. .
    1. Lippi, G, South, AM, Henry, BM. Annals express: electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem 2020. [Epub ahead of print].
    1. Chen, D ,Li, X ,Song, Q, Hu, C, Su, F, Dai, J. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). medRxiv 2020. [Epub ahead of print].
    1. Pan, L, Mu, M, Yang, P, Sun, Y, Yan, J, Li, P, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicentric study. Am J Gastroenterol 2020;115:766–73. [Epub ahead of print].
    1. Chai, X, Hu, L, Zhang, Y, Han, W, Lu, Z, Ke, A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv 2020. [Epub ahead of print].
    1. Feng, G, Zheng, KI, Yan, QQ, Rios, RS, Targher, G, Byrne, CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol 2020;8:18–24. .
    1. Joannidis, M, Forni, LG, Klein, SJ, Honore, PM, Kashani, K, Ostermann, M, et al. Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med 2020;46:654–72. .
    1. Cheng, Y, Luo, R, Wang, K, Zhang, M, Wang, Z, Dong, L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829–38. .
    1. Lippi, G, Lavie, CJ, Sanchis-Gomar, F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis 2020. [Epub ahead of print].
    1. Shi, S, Qin, M, Shen, B, Cai, Y, Liu, T, Yang, F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020. [Epub ahead of print].
    1. Ruan, Q, Yang, K, Wang, W, Jiang, L, Song, J. Clinical predictors of mortality due to COVID- 19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020. [Epub ahead of print].
    1. Arentz, M, Yim, E, Klaff, L, Lokhandwala, S, Riedo, FX, Chong, M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. J Am Med Assoc 2020. [Epub ahead of print].
    1. Holshue, ML, DeBolt, C, Lindquist, S, Lofy, KH, Wiesman, J, Bruce, H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–36. .
    1. Rodriguez-Morales, AJ, Cardona-Ospina, JA, Gutiérrez-Ocampo, E, Villamizar-Peña, R, Holguin-Rivera, Y, Escalera-Antezana, JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infect Dis 2020. [Epub ahead of print].
    1. Agnello, L, Bivona, G, Parisi, E, Lucido, GD, Iacona, A, Ciaccio, AM, et al. Presepsin and midregional proadrenomedullin in pediatric oncologic patients with febrile neutropenia. Lab Med 2020. [Epub ahead of print].
    1. Zaninotto, M, Mion, MM, Cosma, C, Rinaldi, D, Plebani, M. Presepsin in risk stratification of SARS-CoV-2 patients. Clin Chim Acta. 2020;507:161–3. [Epub ahead of print].
    1. Padoan, A, Sciacovelli, L, Basso, D, Negrini, D, Zuin, S, Cosma, C, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta. 2020;507:164–6.
    1. Padoan, A, Cosma, C, Sciacovelli, L, Faggian, D, Plebani, M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med 2020;58:1081–8.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren